Yeni Cleveland Clinic araştırması, ilk kez, lenfoma ve lösemi için FDA onaylı ibrutinib'in (ibrutinib) en yaygın ve ölümcül beyin tümörlerinin tedavisine yardımcı olabileceğini ve bir gün glioblastomalı hastalarda kullanılabileceğini ve hayatta kalma oranlarını iyileştirebileceğini gösteriyor.
American Brain Tumor Association'ın raporuna göre glioblastomanın hayatta kalma oranı çok düşük ve standart tedavi alan hastaların medyan hayatta kalma süresi 15 aydan az. Glioblastoma, en ölümcül birincil beyin tümörüdür ve mevcut tedavilere oldukça dirençlidir. Bu hastalara mümkün olan en kısa sürede yeni tedavilerin sağlanmasına acil ihtiyaç vardır.
In an earlier study, Bao and colleagues found that gliyom stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain tümörler in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
